Victoza liraglutide: Additional Phase III data

Additional data from an open-label, international Phase III trial in 665 patients inadequately controlled with metformin showed that 1.8 mg once-daily subcutaneous Victoza led to significantly higher overall treatment satisfaction as measured by Diabetes Treatment Satisfaction Questionnaire scores at week 26 vs. 100 mg once-daily oral Januvia sitagliptin (4.35 vs. 2.96, p=0.03). Additionally, a significantly higher proportion of patients treated with high-dose Victoza lost >3% of their body weight vs. Januvia (51% vs. 21%, p<0.0001). Data were presented at the European Association for the Study of Diabetes meeting in Stockholm. ...